Janssen Research & Development, LLC

Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous ...

Official Title: 
Daratumumab Subcutaneous Pre-approval Access Study
Brief Summary: 
The purpose of this pre-approval access (PAA) program is to provide treatment to participants with serious/life-threatening diseases or conditions.
Available
EA Type
Individual Patients

Drug: Daratumumab
Daratumumab 1800 milligram (mg) will be administered as a fixed dose by subcutaneous (SC) injection.

Eligibility Criteria: 

Inclusion Criteria:

-

Exclusion Criteria:

-

Eligibility Gender: 
All
Contacts: 

Contact
1-800-JANSSEN (1-800-526-7736)
Janssenmedinfo@its.jnj.com

Janssen Research & Development, LLC Clinical Trial
Study Director
Janssen Research & Development, LLC

Janssen Research & Development, LLC
EA Number: 
MeSH Terms: 
Daratumumab, Antibodies, Monoclonal
Disclaimer:
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.